Le Lézard
Classified in: Health, Business
Subject: FVT

Super Model-Turned-Super Mogul Kathy Ireland Interviews Anpac Bio CEO For 'Worldwide Business with Kathy Ireland'


SACRAMENTO, Calif., April 20, 2018 /PRNewswire/ -- Chris Yu, Chief Executive Officer of international life sciences corporation Anpac Bio-Medical Science Company, was interviewed this week by "Super Model-turned-Super Mogul" Kathy Ireland, for her award-winning, "Worldwide Business with Kathy Ireland", multi-media program; to be aired on, FOX  Business Network, and Bloomberg later this year.

Super Model-turned-Super Mogul Kathy Ireland interviewed Anpac Bio CEO Dr. Chris Yu for an upcoming, "Breakthroughs in Medical Innovation" segment of her award-winning show, "Worldwide Business with Kathy Ireland". Dr. Yu was invited to speak about Anpac Bio's "Cancer Differentiation Analysis" (CDA) liquid biopsy technology, due to the company's 80,000 cases to date  demonstrating CDA identifies 26+ different cancers with a single, standard blood test-usually catching it at the earliest stages.

Invited by the acclaimed, celebrity business empire CEO to appear in a special, "Breakthroughs in Medical Innovation", segment of, "Worldwide Business with Kathy Ireland", Dr. Yu shared with Kathy and her audiences information about Anpac Bio's proprietary, "Cancer Differentiation Analysis" (CDA) liquid biopsy technology ? the only such technology and testing fully-commercialized and available for patient screening worldwide.

Ireland featured Anpac Bio exclusively on "Worldwide Business" due to the company's comprehensive research validity data from 80,000+ cases processed to date, demonstrating CDA diagnostics consistently detects over 26+ cancers -- with a sensitivity and specificity rate range of 75%-90% -- usually identifying the disease at its earliest stages from a single, standard blood test. And it does so without any harmful side effects in patients; generating far fewer "false positives"; at a cost substantially lower than traditional testing; and generating results within minutes of sample submission.

Anpac Bio has filed over 200 CDA-related patent applications worldwide ? 70+ issued currently; and maintains operations in seven sites, employing over 100 people globally.

Described as "game changing", and receiving the, "Breakthrough Innovation Award", at World Nobel Prize Laureate Summit; and named, "Most Promising Cancer Screening Company", at the 2017 Global Precision Medicine Industry Awards, Anpac Bio's CDA technology effectively reinvents early cancer screening and detection.

Kathy Ireland is the CEO of Kathy Ireland Worldwide. kiWW® is listed as one of the most powerful brands in the world by License Global Magazine. Kathy Ireland was named one of the 19 most influential women in licensing by License Global magazine and Fairchild Publications. Kathy graced the cover of Forbes Magazine twice (2012, 2016). kiWW® earns over $2.5 billion dollars in global retail sales annually; and has received multiple awards, including "Good Housekeeping Seals". Kathy and kiWW® support many cancer-related charities such as the St. Jude Children's Research Hospital. UCLA named Kathy one of the, "Top Ten Women's Health Advocates in America" today.

Further information: www.AnpacBio.com.

 

International life sciences leader Anpac Bio-Medical Science Company has developed breakthrough, proprietary, "Cancer Differentiation Analysis" technology that effectively reinvents cancer screening and early detection. Anpac's proprietary CDA medical devices analyze simple, standard, non-invasive "Blood Biopsies" - resulting in measurably greater early cancer detection sensitivity and specificity, with no harmful side effects in patients. The proven results of 25,000 cases to date demonstrate CDA's research validity achieving an average sensitivity and specificity rate range of 75%-90% for ten different types of cancer -- often identifying the type and location of threatening, diseased cancer cells before they form into tumors. (PRNewsFoto/Anpac Bio-Medical Science Co.)

SOURCE Anpac Bio


These press releases may also interest you

at 21:40
TSX VENTURE COMPANIES None today. 24/04/24 - TSX Venture Exchange Bulletins TSX VENTURE COMPANIES BULLETIN V2024-1192 AUKA CAPITAL CORP. ("AUK.P") BULLETIN TYPE:  HaltBULLETIN DATE:  April 24, 2024TSX Venture Tier 2 Company  Effective at 5:10 a.m....

at 21:37
Ademi LLP is investigating HashiCorp for possible breaches of fiduciary duty and other violations of law in its transaction with IBM....

at 21:27
Labcorp , a global leader of innovative and comprehensive laboratory services, announced today that it has been selected as the winning bidder for select assets of Invitae, a leading medical genetics company.  Before the transaction can proceed,...

at 21:26
OKX, a leading Web3 technology company, has issued updates for April 24, 2024. OKX DeFi Launches 'zkSwap Bonus Event' Offering Users...

at 21:19
Invitae , a leading medical genetics company, announced that Labcorp , a global leader of innovative and comprehensive laboratory services, has been selected...

at 20:55
Quorum Information Technologies Inc. ("Quorum"), a North American SaaS Software and Services company providing essential enterprise solutions that automotive dealerships and Original Equipment Manufacturers ("OEMs") rely on for their operations,...



News published on and distributed by: